Lakewood-Amedex Advances Nu-3 Gel with Positive Preclinical Safety Data
Event summary
- Lakewood-Amedex Biotherapeutics reported robust preclinical safety data for Nu-3 Gel, supporting dose selection for an upcoming Phase 2a trial in infected diabetic foot ulcers (iDFU).
- Nu-3 was well-tolerated in FDA-required safety studies at doses higher than those planned for the Phase 2a trial, with low systemic exposure.
- The company plans to evaluate 2%, 5%, and 10% gel formulations in the Phase 2a trial, targeting broad-spectrum antimicrobial activity against resistant bacterial strains.
The big picture
Lakewood-Amedex's progress with Nu-3 Gel underscores the growing need for novel antimicrobial treatments targeting resistant infections. The company's focus on topical formulations with low systemic side effects aligns with broader industry trends toward safer, more targeted therapies in infectious disease management.
What we're watching
- Clinical Execution
- How the initiation and progress of the Phase 2a trial will validate Nu-3's safety and efficacy in human subjects.
- Regulatory Pathway
- Whether the positive preclinical data will facilitate a smoother regulatory approval process for Nu-3 Gel.
- Market Differentiation
- The pace at which Lakewood-Amedex can position Nu-3 as a differentiated treatment option in the infected diabetic foot ulcer market.
Related topics